David Dankort

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5201908/publications.pdf Version: 2024-02-01



ΠΑΝΙΟ ΠΑΝΙΚΟΡΤ

#	Article	IF	CITATIONS
1	MOB3A Bypasses BRAF and RAS Oncogene-Induced Senescence by Engaging the Hippo Pathway. Molecular Cancer Research, 2022, 20, 770-781.	3.4	9
2	Metabolic Regulator IAPP (Amylin) Is Required for BRAF and RAS Oncogene-Induced Senescence. Molecular Cancer Research, 2021, 19, 874-885.	3.4	2
3	Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses. Journal of Clinical Investigation, 2021, 131, .	8.2	35
4	Construction of Modular Lentiviral Vectors for Effective Gene Expression and Knockdown. Methods in Molecular Biology, 2016, 1448, 3-21.	0.9	5
5	TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis. Cancer Research, 2015, 75, 3167-3180.	0.9	25
6	mTORC1 Activation Blocks BrafV600E-Induced Growth Arrest but Is Insufficient for Melanoma Formation. Cancer Cell, 2015, 27, 41-56.	16.8	106
7	The inhibitor of kappa B kinase-epsilon regulates MMP-3 expression levels and can promote lung metastasis. Oncogenesis, 2014, 3, e116-e116.	4.9	5
8	RAS Transformation Requires CUX1-Dependent Repair of Oxidative DNA Damage. PLoS Biology, 2014, 12, e1001807.	5.6	51
9	Ras Effector Mutant Expression Suggest a Negative Regulator Inhibits Lung Tumor Formation. PLoS ONE, 2014, 9, e84745.	2.5	19
10	Oncogeneâ€dependent control of <scp>miRNA</scp> biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma. Journal of Pathology, 2013, 229, 132-140.	4.5	34
11	Hematopoietic Expression of Oncogenic <i>BRAF</i> Promotes Aberrant Growth of Monocyte-Lineage Cells Resistant to PLX4720. Molecular Cancer Research, 2013, 11, 1530-1541.	3.4	7
12	A Modular Lentiviral and Retroviral Construction System to Rapidly Generate Vectors for Gene Expression and Gene Knockdown In Vitro and In Vivo. PLoS ONE, 2013, 8, e76279.	2.5	13
13	B-Raf Activation Cooperates with PTEN Loss to Drive c-Myc Expression in Advanced Prostate Cancer. Cancer Research, 2012, 72, 4765-4776.	0.9	87
14	Abrogation of BRAF ^{V600E} -induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes and Development, 2012, 26, 1055-1069.	5.9	229
15	A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma. Cancer Discovery, 2012, 2, 685-693.	9.4	264
16	Mutationally Activated BRAFV600E Elicits Papillary Thyroid Cancer in the Adult Mouse. Cancer Research, 2011, 71, 3863-3871.	0.9	87
17	β-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient Melanomas. Cancer Cell, 2011, 20, 741-754.	16.8	317
18	Functional relevance of the histone γH2Ax in the response to DNA damaging agents. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 8663-8667.	7.1	112

DAVID DANKORT

#	Article	IF	CITATIONS
19	Characterization of Melanoma Cells Capable of Propagating Tumors from a Single Cell. Cancer Research, 2010, 70, 388-397.	0.9	109
20	A Novel Wide Field-of-View Imaging System for Real-Time, Intra-Operative Tumor Bed Assessment. , 2010, ,		0
21	Abstract 4316: A novel wide field-of-view imaging device for real-time, intra-operative tumor bed assessment. , 2010, , .		0
22	BrafV600E cooperates with Pten loss to induce metastatic melanoma. Nature Genetics, 2009, 41, 544-552.	21.4	1,022
23	A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes and Development, 2007, 21, 379-384.	5.9	427
24	The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation. Oncogene, 2005, 24, 7599-7607.	5.9	68
25	ErbB2 overexpression in mammary cells upregulates VECF through the core promoter. Biochemical and Biophysical Research Communications, 2005, 326, 455-465.	2.1	30
26	The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2345-2350.	7.1	69
27	Modulation of Erbb2 signaling during development: a threshold level of Erbb2 signaling is required for development. Development (Cambridge), 2004, 131, 5551-5560.	2.5	15
28	Memo mediates ErbB2-driven cell motility. Nature Cell Biology, 2004, 6, 515-522.	10.3	112
29	Genetic identification of effectors downstream of Neu (ErbB-2) autophosphorylation sites in a Drosophila model. Oncogene, 2003, 22, 1916-1926.	5.9	10
30	Distinct tyrosine autophosphorylation sites mediate induction of epithelial mesenchymal like transition by an activated ErbB-2/Neu receptor. Oncogene, 2001, 20, 788-799.	5.9	57
31	Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins. Journal of Biological Chemistry, 2001, 276, 38921-38928.	3.4	74
32	Grb2 and Shc Adapter Proteins Play Distinct Roles in Neu (ErbB-2)-Induced Mammary Tumorigenesis: Implications for Human Breast Cancer. Molecular and Cellular Biology, 2001, 21, 1540-1551.	2.3	147
33	Signal transduction in mammary tumorigenesis: a transgenic perspective. Oncogene, 2000, 19, 1038-1044.	5.9	87
34	Oncogene-mediated signal transduction in transgenic mouse models of human breast cancer. Endocrine-Related Cancer, 1997, 4, 75-84.	3.1	0